These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 34532592)

  • 1. Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives.
    Battaglin F; Puccini A; Naseem M; Schirripa M; Berger MD; Tokunaga R; McSkane M; Khoukaz T; Soni S; Zhang W; Lenz HJ
    J Cancer Metastasis Treat; 2018; 4(3):. PubMed ID: 34532592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in colorectal cancer: Current clinical utility and future perspectives.
    Vacante M; Borzì AM; Basile F; Biondi A
    World J Clin Cases; 2018 Dec; 6(15):869-881. PubMed ID: 30568941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation.
    Chung C
    J Oncol Pharm Pract; 2022 Jun; 28(4):850-869. PubMed ID: 33832365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer.
    Kasi PM; Koep T; Schnettler E; Shahjehan F; Kamatham V; Baldeo C; Hughes CL
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819873924. PubMed ID: 31533552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Developing Story of Predictive Biomarkers in Colorectal Cancer.
    Boussios S; Ozturk MA; Moschetta M; Karathanasi A; Zakynthinakis-Kyriakou N; Katsanos KH; Christodoulou DK; Pavlidis N
    J Pers Med; 2019 Feb; 9(1):. PubMed ID: 30736475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of tumor angiogenesis as a therapeutic target in colorectal cancer.
    Battaglin F; Puccini A; Intini R; Schirripa M; Ferro A; Bergamo F; Lonardi S; Zagonel V; Lenz HJ; Loupakis F
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):251-266. PubMed ID: 29338550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments.
    Bruera G; Ricevuto E;
    Pharmgenomics Pers Med; 2020; 13():601-617. PubMed ID: 33235483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma.
    Rachiglio AM; Sacco A; Forgione L; Esposito C; Chicchinelli N; Normanno N
    Explor Target Antitumor Ther; 2020; 1(1):53-70. PubMed ID: 36046264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
    Nakamura Y; Yoshino T
    Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy.
    De Mattia E; Roncato R; Palazzari E; Toffoli G; Cecchin E
    Front Pharmacol; 2020; 11():897. PubMed ID: 32625092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.
    Battaglin F; Naseem M; Lenz HJ; Salem ME
    Clin Adv Hematol Oncol; 2018 Nov; 16(11):735-745. PubMed ID: 30543589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer.
    Martini G; Dienstmann R; Ros J; Baraibar I; Cuadra-Urteaga JL; Salva F; Ciardiello D; Mulet N; Argiles G; Tabernero J; Elez E
    Ther Adv Med Oncol; 2020; 12():1758835920936089. PubMed ID: 32782486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal Cancer Biomarkers in the Era of Personalized Medicine.
    Patel JN; Fong MK; Jagosky M
    J Pers Med; 2019 Jan; 9(1):. PubMed ID: 30646508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
    Battaglin F; Dadduzio V; Bergamo F; Manai C; Schirripa M; Lonardi S; Zagonel V; Loupakis F
    Expert Opin Biol Ther; 2017 Oct; 17(10):1297-1308. PubMed ID: 28752777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Siena S
    Handb Exp Pharmacol; 2018; 249():145-159. PubMed ID: 28382467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.